Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
International Journal of Clinical Pharmacology and Therapeutics|April 1, 1994
Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice dailyJ Götz, R Sauter, V W Steinijans, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|August 1, 1991
Lack of pharmacokinetic interaction as an equivalence problemV W Steinijans, M Hartmann, R Huber, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1996
Lack of pharmacokinetic interaction as an equivalence problemV W Steinijans, M Hartmann, R Huber, et al.
Clinical Pharmacology and Therapeutics|March 1, 1991
The influence of caffeine on the steady-state pharmacokinetics of theophyllineJ H Jonkman, F A Sollie, R Sauter, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|August 1, 1986
Once daily theophylline: multiple-dose comparison of an encapsulated micro-osmotic system (Euphylong) with a tablet (Uniphyllin)V W Steinijans, H U Schulz, W Beier, et al.
Pneumologie (Stuttgart, Germany)|November 1, 1991
[Chronotherapy concept and the pharmacokinetic validation of a theophylline retard preparation for once-nightly administration (Euphylong)]V W Steinijans, R Sauter, A Böhm, et al.
Arzneimittel-Forschung|August 1, 1988
A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalenceV W Steinijans, R Dietrich, H Trautmann, et al.
Clinical Pharmacokinetics|March 1, 1988
Clinical pharmacokinetics of urapidilR Kirsten, K Nelson, V W Steinijans, et al.
Pharmacology|March 11, 1998
Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlatesW Kromer, U Krüger, R Huber, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 1, 1996
Pharmacokinetics and drug interactions--relevant factors for the choice of a drugK Zech, V W Steinijans, R Huber, et al.
Pageof 11